Full Year 2026 Aspen Pharmacare Holdings Ltd Earnings Call Transcript
Key Points
- Aspen Pharmacare Holdings Ltd (APNHF) achieved 28% growth in normalized headline earnings per share (NHEPS) from continuing operations, driven by strong operating leverage and efficiency gains.
- The company generated robust free cash flow of ZAR3.8 billion, a significant improvement from near breakeven in the prior year, supported by lower capital expenditure and improved working capital management.
- Aspen Pharmacare Holdings Ltd (APNHF) successfully reshaped its sterile manufacturing business, more than offsetting the ZAR1 billion loss from the mRNA contract with ZAR1.2 billion in EBITDA growth, and raised its FY27 sterile EBITDA guidance to ZAR2.2 billion.
- Commercial pharma delivered double-digit EBITDA growth of 13% in constant exchange rate, driven by strong momentum in emerging markets, particularly South Africa and Brazil, with Mounjaro capturing 53% of the South African GLP-1 market.
- The company ended the year in a net cash position of ZAR0.8 billion after the ZAR28 billion APAC divestment, providing financial flexibility for capital allocation, including a ZAR2 billion share buyback program.
- Aspen Pharmacare Holdings Ltd (APNHF) is making significant progress in its GLP-1 generic rollout, with registrations in Canada and submissions in emerging markets like Kenya and Nigeria, positioning for future growth.
- The company expects substantial future growth, guiding to at least ZAR9 billion in normalized EBITDA for FY27, implying over 50% growth in NHEPS, driven by sterile manufacturing recovery and commercial pharma growth.
- Group revenue was flat in constant exchange rate, with a 10% decline in manufacturing revenue due to the loss of the mRNA contract, highlighting ongoing top-line pressure.
- The company incurred significant one-off charges, including ZAR2.3 billion in intangible asset impairments and ZAR2.3 billion in restructuring costs, which impacted reported earnings.
- The Middle East conflict negatively impacted commercial pharma sales and profitability, particularly in the OTC segment, and also disrupted supply chains for key inputs like solvents and plastics.
- The GLP-1 generic rollout faces uncertainties, including an API supply issue in Canada that could delay product availability, with no clear resolution expected for at least three weeks.
- The APAC divestment will result in a loss of approximately ZAR600 million in free cash flow annually, which the company must offset to achieve its targeted stronger cash flow in FY27.
- The company's China reshape program led to product discontinuations, which diluted overall revenue growth and will continue to impact top-line performance in the near term.
- Currency fluctuations, particularly a strong South African rand, negatively affected reported revenues, and the company expects continued currency volatility to impact future results.
Good morning, and welcome to Aspen Pharmacare's 2026 Annual Financial Presentation. Thank you all for joining us this morning. Just to quickly run you through the agenda this morning, Stephen Saad is going to give us an introduction and overview.
He will then hand over to Sean Capazorio, our Chief Financial Officer, who will run through the financial performance for the and Stephen will then return to give us an overview of the operational update, strategic updates and financial guidance for the next financial year.
We'll conclude with a Q&A session. So please feel free to send questions through via the webcast. We'll get to as many as we can with the time available, please do identify yourself Again, if we don't get, then we'll follow up with you over the next couple of days.
With that, I'm going to welcome up Stephen side, our Chief Executive Officer, to give us an introduction. Thank you, Stephen.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
